News - Medicinapersonalizada

During the day, the Minister chaired a meeting with research staff from the Genomic Medicine Unit in which she was able to learn about the progress of the NAGEN Program projects that the centre has been developing since 2016 and the Infrastructure for Precision Medicine associated with Science and Technology (IMPaCT), which is coordinated nationally by the Carlos III Institute of Health (ISCIII) and centralised in Navarre at Navarrabiomed.

The Regional Minister of Health, Fernando Domínguez, presied today the presentation of the IMPaCT Cohort study at the Lezkairu health centre. This study aims to carry out an exhaustive health study of 200,000 people representative of the Spanish population over the next 20 years, 4,000 in Navarra, in order to better understand the origin of the main diseases, thus helping to prevent and treat them, promoting personalised and precision medicine. The event was also attended by Patricia Palacio and Óscar Lecea, principal investigator and collaborator of the study in Navarre, respectively, and the Primary Care manager, Susana Miranda.

The Multidisciplinary Unit for Child and Adolescent Cancer (UMDCIA) of the University Hospital of Navarre diagnosed and treated a total of 22 new cases of cancer in 2023, all of them in patients aged between 1 month and 16 years.

Researchers at the Cima-University of Navarra identified a ribonucleic acid (RNA) that could modulate gene therapy against cancer and other pathologies. These results guide the development of personalised treatments for each patient and at different stages of their disease.

On February 16th from 11:30 to 16:00 the Workshop "GENE THERAPY AND PRECISION MEDICINE IN RARE DISEASES" will take place in the Assembly Hall of the Main Building of the University Hospital of Navarra (HUN). The conference is aimed mainly for health sciences students, residents, health professionals and health research or patient associations.

The University Hospital of Navarre (HUN) of the Navarre Healthcare System (SNS-O) selected as an affiliated entity for the Network of Comprehensive Cancer Centers of the European Union, a joint action called CraNE, in response to the Flagship Initiative number 5 of the European Board Cancer Plan (EBCP).